Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Journal: Cancer Cell

Published: 2018-04-12

DOI: 10.1016/j.ccell.2018.03.018

Affiliations: 34

Authors: 32

Go to article
Institutions FC
BMS Princeton, United States of America (USA) 0.16
Department of Genetics and Genomic Sciences, ISMMS, United States of America (USA) 0.14
Ludwig Collaborative Laboratory at MSK, United States of America (USA) 0.11
Department of Medicine, MSKCC, United States of America (USA) 0.10
Fiona and Stanley Druckenmiller Center for Lung Cancer Research, MSKCC, United States of America (USA) 0.09
Weill Cornell Medicine (WCM), Cornell University, United States of America (USA) 0.07
Department of Pathology, MSKCC, United States of America (USA) 0.06
Department of Immunology, MOFFITT, United States of America (USA) 0.06
Parker Institute for Cancer Immunotherapy, United States of America (USA) 0.03
Fox Chase Cancer Center (FCCC), Temple University, United States of America (USA) 0.03
Department of Epidemiology and Biostatistics, MSKCC, United States of America (USA) 0.03
CRUK Lung Cancer Centre of Excellence, United Kingdom (UK) 0.03
UCL Cancer Institute, United Kingdom (UK) 0.03
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, MSKCC, United States of America (USA) 0.02
Human Oncology and Pathogenesis Program (HOPP), MSKCC, United States of America (USA) 0.02
Department of Microbiology and Immunology, MUSC, United States of America (USA) 0.02
Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, United Kingdom (UK) 0.01

Return